{"ticker": {"uuid": "80fe1174-c805-4142-9257-7d8a46a93816", "symbol": "ALGS", "name": "Aligos Therapeutics\u00a0Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "H.C. Wainwright Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $50", "summary": "H.C. Wainwright has reiterated its Buy rating for Aligos Therapeutics (ALGS.US) and maintained a target price of $50. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance and potential.", "url": "https://www.moomoo.com/news/post/72927973/hc-wainwright-maintains-aligos-therapeutics-algsus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-15T01:41:20", "published_display": "15 Jul 2026 01:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Aligos stock rating on trial enrollment By Investing.com", "summary": "H.C. Wainwright has reiterated a Buy rating and a $50.00 price target for Aligos Therapeutics Inc. following the completion of enrollment in its Phase 2 B-SUPREME trial for chronic hepatitis B virus infection. The trial over-enrolled participants, leading to an anticipated earlie", "url": "https://m.au.investing.com/news/stock-market-news/hc-wainwright-reiterates-aligos-stock-rating-on-trial-enrollment-93CH-4532149?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-07-14T11:58:16", "published_display": "14 Jul 2026 11:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Aligos stock rating on trial enrollment", "summary": "H.C. Wainwright has reiterated a Buy rating and a $50.00 price target for Aligos Therapeutics Inc. (NASDAQ:ALGS) after the company completed enrollment for its Phase 2 B-SUPREME trial, which is evaluating pevifoscorvir sodium for chronic hepatitis B. Aligos over-enrolled one coho", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-aligos-stock-rating-on-trial-enrollment-93CH-4790650", "source_name": "Investing.com", "published_at": "2026-07-14T07:54:00", "published_display": "14 Jul 2026 07:54", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection", "summary": "Aligos Therapeutics has announced the completion of enrollment for its Phase 2 B-SUPREME study of pevifoscorvir sodium, a treatment for chronic hepatitis B virus (HBV) infection. The study successfully enrolled both HBeAg+ and HBeAg- participants, with topline safety and efficacy", "url": "https://investingnews.com/aligos-therapeutics-announces-the-completion-of-enrollment-in-the-phase-2-b-supreme-study-of-pevifoscorvir-sodium-under-development-for-the-treatment-of-chronic-hbv-infection/", "source_name": "Investing News Network", "published_at": "2026-07-14T01:40:01", "published_display": "14 Jul 2026 01:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics (ALGS) Completes Enrollment for Phase 2 Stud", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPUHQ5UExrbVNvX2szNWlzaVpHcUFxNWoxTHFLTkRiMmtIcWJvU2w2N2o5RTBOYk1nRENOdnZvVHdwZTlxMkxRNUhPdmN2VnNLa3o3eUpLaGZ6R29kOGt3VkVOOGRjazZtSU1Ia0tkLTY0bmV0ZXdoSGw2VDJ2WTlXc0ZNWGVTb0NuZ3U4QlVVZWJIWXRraHhMZzFkTVRvQXhrUFZNag?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T13:05:38+00:00", "published_display": "13 Jul 2026 13:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics Completes Enrollment in Phase 2 Study of Potential Chronic Hepatitis B Treatment", "summary": "Aligos Therapeutics has announced the completion of enrollment for its Phase 2 study of ALG-000184, an investigational capsid assembly modulator for chronic hepatitis B (CHB). The study aims to evaluate the safety and efficacy of the treatment in patients with CHB, bringing the c", "url": "https://www.moomoo.com/news/post/72861717/aligos-therapeutics-completes-enrollment-in-phase-2-study-of-potential?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T13:42:16", "published_display": "13 Jul 2026 13:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aligos completes enrollment in phase 2 hepatitis B study", "summary": "Aligos Therapeutics Inc. has completed enrollment for its Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic hepatitis B, enrolling 131 HBeAg+ and 114 HBeAg- participants. The company expects topline safety and efficacy data by late Q3 2027. Aligos has also secured a lic", "url": "https://www.investing.com/news/company-news/aligos-completes-enrollment-in-phase-2-hepatitis-b-study-93CH-4788395", "source_name": "Investing.com", "published_at": "2026-07-13T12:11:43", "published_display": "13 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pevifoscorvir HBV trial fully enrolled; first key data expected in late 3Q 2027", "summary": "Aligos Therapeutics announced the completion of enrollment for its global Phase 2 B-SUPREME study of pevifoscorvir sodium, targeting chronic hepatitis B virus (HBV) infection. Both HBeAg+ and HBeAg- cohorts are now fully enrolled, with 131 and 114 participants respectively. Topli", "url": "https://www.stocktitan.net/news/ALGS/aligos-therapeutics-announces-the-completion-of-enrollment-in-the-2wuvwz2xpj5t.html", "source_name": "Stock Titan", "published_at": "2026-07-13T11:59:43", "published_display": "13 Jul 2026 11:59", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avoiding Lag: Real-Time Signals in (ALGS) Movement", "summary": "This article provides a real-time analysis of Aligos Therapeutics Inc. (NASDAQ: ALGS) stock movement, highlighting a strong near and mid-term sentiment despite a weak long-term outlook. It identifies a mid-channel oscillation pattern and an exceptional 94.0:1 risk-reward setup, o", "url": "https://news.stocktradersdaily.com/news_release/149/Avoiding_Lag:_Real-Time_Signals_in_ALGS_Movement_071326022802_1783924082.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T02:28:00", "published_display": "13 Jul 2026 02:28", "sentiment": "positive", "sentiment_pct": 63, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALGS Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "The article provides an overview of Aligos Therapeutics Inc (ALGS) financial performance, focusing on its revenue breakdown, profitability margins, and a comparison with competitors. ALGS maintains a strong gross margin of 100.00% but shows negative operating and net margins, ind", "url": "https://intellectia.ai/en/stock/ALGS/financials", "source_name": "Intellectia AI", "published_at": "2026-07-10T01:12:13", "published_display": "10 Jul 2026 01:12", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX)", "summary": "Two healthcare companies, Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX), have received bullish analyst ratings. H.C. Wainwright reiterated a Buy rating for Aligos Therapeutics with a $50 price target, while Truist Financial and Barclays maintained Buy ratings for V", "url": "https://www.theglobeandmail.com/investing/markets/stocks/VRTX/pressreleases/3182754/analysts-offer-insights-on-healthcare-companies-aligos-therapeutics-algs-and-vertex-pharmaceuticals-vrtx/", "source_name": "The Globe and Mail", "published_at": "2026-07-09T11:39:59", "published_display": "09 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Aligos Therapeutics stock rating at buy", "summary": "H.C. Wainwright has reiterated a Buy rating and $50.00 price target for Aligos Therapeutics (NASDAQ: ALGS), citing the company's differentiated hepatitis B drug candidate, pevifoscorvir sodium. The firm noted that the B-SUPREME trial is nearing full enrollment, and topline primar", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-aligos-therapeutics-stock-rating-at-buy-93CH-4781357", "source_name": "Investing.com", "published_at": "2026-07-09T11:12:13", "published_display": "09 Jul 2026 11:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Aligos Therapeutics stock rating at buy By Investing.com", "summary": "H.C. Wainwright has reiterated its Buy rating and a $50.00 price target for Aligos Therapeutics (NASDAQ:ALGS), citing the potential of its hepatitis B drug candidate, pevifoscorvir sodium, as a differentiated therapy. The company's recent strategic partnership with Xiamen Amoytop", "url": "https://ca.investing.com/news/stock-market-news/hc-wainwright-reiterates-aligos-therapeutics-stock-rating-at-buy-93CH-4724997", "source_name": "Investing.com Canada", "published_at": "2026-07-08T11:10:53", "published_display": "08 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics stock jumps on $25M China licensing deal", "summary": "Aligos Therapeutics Inc. shares surged 21% after announcing a $25 million upfront payment from an exclusive licensing agreement with Xiamen Amoytop Biotech Co., Ltd. for its chronic hepatitis B drug, pevifoscorvir sodium, in Greater China. The deal also includes up to $420 millio", "url": "https://www.investing.com/news/stock-market-news/aligos-therapeutics-stock-jumps-on-25m-china-licensing-deal-93CH-4777342", "source_name": "Investing.com", "published_at": "2026-07-07T11:39:33", "published_display": "07 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 92, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics Stock Is Trending Overnight: Here's What's Going On With ALGS Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPbEpWcXdoRzI0UnR0U0dhbGJXQmJBdERpeWQwa0FMbzQ2UzNrVUFLMzdsQzFGWENwRFBSakFRRnU2dThVUlJLUmtETmpPUjg1WGRZZHNVXzF0TWlDMnF6dHUzaGVKdFJib2xFOEtRUVRCeW9zdTEyRU5pRDNSQ19nTEFPYWplQ0FpVmhYUG9VbkZCSnRkWUhwRVpCS1h0U09jODBnLThVWmR6WjJraXotak11RlpReFItRV9tRlN3Vmk0QmozWEVPdEZyT2VYdXBXdWc?oc=5", "source_name": "Sahm", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal", "summary": "Aligos Therapeutics (ALGS) shares surged 21% after-hours following a $25 million upfront payment from its Chinese licensing partner, Xiamen Amoytop Biotech. This payment provides non-dilutive funding, bolstering Aligos's financial position, which stood at $54.9 million in cash as", "url": "https://www.tradingview.com/news/stocktwits:fe893c603094b:0-algs-stock-rallies-16-after-hours-on-25m-cash-boost-from-china-hepatitis-b-drug-deal/", "source_name": "TradingView", "published_at": "2026-07-06T23:40:12", "published_display": "06 Jul 2026 23:40", "sentiment": "positive", "sentiment_pct": 92, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics' Shares Rally Following $25M Payment From Xiamen Amoytop Biotech", "summary": "Aligos Therapeutics (ALGS) shares rallied after receiving a $25 million milestone payment from its partner Xiamen Amoytop Biotech. This payment was triggered by the investigational new drug (IND) approval for a new compound targeting chronic hepatitis B (CHB). The collaboration, ", "url": "https://www.moomoo.com/news/post/72541625/aligos-therapeutics-shares-rally-following-25m-payment-from-xiamen-amoytop?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-06T22:40:12", "published_display": "06 Jul 2026 22:40", "sentiment": "positive", "sentiment_pct": 94, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics stock jumps on $25M China licensing deal By Investing.com", "summary": "Aligos Therapeutics (NASDAQ: ALGS) saw its stock jump 21% in after-hours trading following a licensing deal with Xiamen Amoytop Biotech Co., Ltd., which includes a $25 million upfront payment. The agreement grants Amoytop exclusive rights to develop and commercialize pevifoscorvi", "url": "https://za.investing.com/news/stock-market-news/aligos-therapeutics-stock-jumps-on-25m-china-licensing-deal-93CH-4356977", "source_name": "Investing.com South Africa", "published_at": "2026-07-06T22:10:12", "published_display": "06 Jul 2026 22:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Gets $25 Million Upfront Payment From Licensing Deal", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/aligos-gets-25-million-upfront-203416268.html", "source_name": "MT Newswires", "published_at": "2026-07-06T20:34:16+00:00", "published_display": "06 Jul 2026 20:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection", "summary": "Aligos Therapeutics (Nasdaq: ALGS) has received a $25 million upfront payment from Xiamen Amoytop Biotech Co., Ltd. for the exclusive license of pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection. This deal also includes potential milestone paymen", "url": "https://investingnews.com/aligos-therapeutics-receives-upfront-payment-of-25m-usd-from-the-exclusive-license-deal-of-pevifoscorvir-sodium-in-greater-china-for-chronic-hepatitis-b-virus-infection/", "source_name": "Investing News Network", "published_at": "2026-07-06T20:40:12", "published_display": "06 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos receives $25M upfront payment from China licensing deal", "summary": "Aligos Therapeutics Inc. has received a $25 million upfront payment from its licensing agreement with Xiamen Amoytop Biotech Co., Ltd. for pevifoscorvir sodium in Greater China. The deal includes potential milestone payments of up to $420 million and royalties, extending Aligos's", "url": "https://www.investing.com/news/company-news/aligos-receives-25m-upfront-payment-from-china-licensing-deal-93CH-4777348", "source_name": "Investing.com", "published_at": "2026-07-06T20:39:35", "published_display": "06 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "China grants breakthrough status to Aligos\u2019 HBV drug after $25M deal", "summary": "Aligos Therapeutics has received a $25 million upfront payment from Amoytop for the exclusive license of pevifoscorvir sodium in Greater China for chronic hepatitis B. The drug has also been granted Breakthrough Therapy Designation in China, making it eligible for priority review", "url": "https://www.stocktitan.net/news/ALGS/aligos-therapeutics-receives-upfront-payment-of-25m-usd-from-the-3dzov2xu3pw6.html", "source_name": "Stock Titan", "published_at": "2026-07-06T19:39:34", "published_display": "06 Jul 2026 19:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Aligos Therapeutics stock surging today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNMFNVMWc1dmtuVldXNmJGT3hVbHIxck9xUGhtQUdfaHZhM3VibUZfdDVNRGtuRDluR2l5Y3dkZkdQR2lINlNiQmdvLXBpQ2pGcUNMNXNwczFOdGZqUlZ2QVlhMUJvbWVWNFdqanFsdEFKcmFUTzVPWU10NzJPX3FUbVlpUFZwSWgyU19IakpNclp1UnF4VVR0S0JONFY4WjFZX1dsUlQxS1U0ZFZN?oc=5", "source_name": "Investing.com", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discipline and Rules-Based Execution in ALGS Response", "summary": "This article provides an in-depth analysis of Aligos Therapeutics Inc. (NASDAQ: ALGS), highlighting mixed sentiment and choppy conditions across various time horizons. It details specific institutional trading strategies, including position, momentum, and risk hedging, with defin", "url": "https://news.stocktradersdaily.com/news_release/151/Discipline_and_Rules-Based_Execution_in_ALGS_Response_070226012002_1782969602.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-02T01:40:11", "published_display": "02 Jul 2026 01:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics (ALGS) director granted 5,860 stock options at $5.50", "summary": "Aligos Therapeutics director Heather Preston was granted 5,860 stock options with an exercise price of $5.50 per share, expiring on June 25, 2036. These options will vest fully on the earlier of the first anniversary of the June 25, 2026 grant date or just before the company\u2019s 20", "url": "https://www.stocktitan.net/sec-filings/ALGS/form-4-aligos-therapeutics-inc-insider-trading-activity-22d149254b22.html", "source_name": "Stock Titan", "published_at": "2026-06-30T08:10:05", "published_display": "30 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics (ALGS) director granted 5,860 stock options at $5.50 strike", "summary": "Aligos Therapeutics director Margarita Chavez was granted 5,860 stock options with an exercise price of $5.50 per share, expiring in 2036. These options will vest 100% on the earlier of the first anniversary of the June 25, 2026 grant date or Aligos Therapeutics' 2027 annual stoc", "url": "https://www.stocktitan.net/sec-filings/ALGS/form-4-aligos-therapeutics-inc-insider-trading-activity-9f068ee6426a.html", "source_name": "Stock Titan", "published_at": "2026-06-30T07:41:04", "published_display": "30 Jun 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics (ALGS) director receives stock options for 5,860 shares at $5.50", "summary": "Aligos Therapeutics director Peter Hirth was granted stock options for 5,860 shares at an exercise price of $5.50 per share. These options will vest on the earlier of the first anniversary of the grant date or immediately before the 2027 annual stockholder meeting, provided conti", "url": "https://www.stocktitan.net/sec-filings/ALGS/form-4-aligos-therapeutics-inc-insider-trading-activity-742043c26357.html", "source_name": "Stock Titan", "published_at": "2026-06-30T07:41:04", "published_display": "30 Jun 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics (ALGS) director granted 5,860 options at $5.50 strike", "summary": "Aligos Therapeutics director Bridget A. Martell was granted 5,860 stock options at an exercise price of $5.50 per share. These options vest 100% on the earlier of the first anniversary of the grant date or immediately before the company's 2027 annual stockholder meeting, continge", "url": "https://www.stocktitan.net/sec-filings/ALGS/form-4-aligos-therapeutics-inc-insider-trading-activity-6b4e9c7f3db1.html", "source_name": "Stock Titan", "published_at": "2026-06-30T07:41:03", "published_display": "30 Jun 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Aligos (ALGS) granted option on 5,860 common shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQQTMteEFEcGJvMENkQlgyTDZ2T3FqcGFwVkZZZHhwOWRTbEREMXdLSEloMWJ0V2dmYzRPVW01bk0xY1pvVGFKenZDbnZXdHM3YVRCaEtBX2l3NVRBMVloRmVaT05vdi01aHI4OWlQek1xQmtKZXpqOWNlWFFHLS1BUG1JUmVqcUZzNFF1MHlQa09LblB6VWhfZjY5WTE3akhFRkhXdUpZNHUxVC12MFg4djhBZlgtX0kw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics (ALGS) director gets 5,860-share stock option grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQT3Y1VTRGWHFZSG40RzliamJZbmlXbnVHZ05IX09mczVSTkN6QnNpa3ZQYWUtNlFMMGpDTEJLY0pkV1hXbGtOZmZacVlOcGx4OURqYWNOc0lUbUpZSExwNk9oS0pUak5BckZxcFZiU2ktRWtIQWdQTkpacGdINW85TXJTYmZ6eDJpNlY1M2E4WDZYM3IweFp5NEVENzctYVY2ZnFIS1pxc2RrVlBRUVUxSFVrZnRaYmZK?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics (ALGS) shareholders approve ESPP changes and annual say-on-pay", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQVDdnOHBkQ19FeVQwM040LWFVU3hEbHlfSUFWaFZvX1Fjd3BJakpieHM0Vk9pQklqWTB2Z19SQUtXZDdWS1VvUVR0WlNfTS1iRTlJamt1R1JBQmNlUWF3bmt0VFpzcTA1SzhqNnBtRXV1czNoTm5FdG5qSWJFdnZsekVmZklNTzkxT3JtWHYwTzZxaXlaNHpOdmtTRjZ1c1FNa2dJS1ZpUkl3NW84QVRlZldn?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics (NASDAQ: ALGS) CEO discloses 5.6% stake in Schedule 13D filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQX0NoVlNodnotTmR3U29jUGJrWFNqcmN6eWpMTnJSNDlJR2pDUkFteFJVWEpnRDdjYm5lSktSekExaVNFeWFqZUdpdGlLbFQzY2hkS0MwdHk1b0NfeE85RVR0XzlXVUI3ZlJDNzBnN3Z1U0dUNkxJNzZsOE1BWVN3MGxUaks4MW9KSHp5QS04Z09JWURYU2R3VmdqOF9ZTXNzNEFVTXZsSWllMnlPeWtoMXpVSjlLMERDa05JQzFKYU5NcXpzZ3plNkZB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're A Bit Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxOamVpVUtMLXUxN3ZhSFhKYjBaTjFtZ0V2NkNVdjlCdzhTUUNuWW5seWIwbU5HcXAtaTFqUHVjUUpIM1kxcUt0WXBiSHdZV21HMm56N1EwQk9LbUlDS25hTERuYnB3eEEyZ3hOdGx3elNBUGR0MUwxT1RQVC02ZURvaXJyRDEyZXpTeC12QXI1eTU1WGpNX3NJZTRiY3BUbzM1aXFfSERHUmVTdFh2NDV6M01pLTNld2FvU0g0NmFIQkFjbHp5MzZyNUo1bG1mWVNxR20zMVk2d1ZkVUQyMGRISk9wWTVON0ZwZ1Y40gHwAUFVX3lxTE56aGprTDUwN0duS2F6ZWlERkZzTnVTWUdobXp6bzh5T096QVV5QjY5b1JfM2F5Ny1DTjNxOW16cDdMbkpTQnVVMFJCX3FsTHBJNzg3bjl2SExoTW9jWWY4cWt6MlRhcEkxSDljUDl4RGNEVHBTNldYTmo4bEt3S0doanhrR1ZVbkVEYS1qeDE1SWZxR0RXZTRCTlNVVkNwTHhSZklKcFNjUUNPN2dhY2YyZjN3c0VROW5CTHo2ZEtQS0RONEF6Vkxha1hEdzIyNzFpWjQtc1F2NFJRWS04T3NXejdJUHU4V0EtaXVMbkJiNw?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lake Street Initiates Aligos Therapeutics With Buy Rating, $45 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/lake-street-initiates-aligos-therapeutics-120449124.html", "source_name": "MT Newswires", "published_at": "2026-05-28T12:04:49+00:00", "published_display": "28 May 2026 12:04", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hepatitis B data: 40% on Aligos drug reach HBsAg level used for cure regimens", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOeGlMbWo2OTZrd3VzSWhWRnJ1ZUJjaTh6WVpUcWllZktoQ213eUxwSU83Yjh4b09qdVhHWXRMY2tWVjhkM1AyNGV0bFZBaVlwX1FBbmRFcmRIU2xqdlh6TnNXZkpnNWR1U2VONzJVWS1iQktPdFdPOUxOeGVMWVFxZy1sVXBUZVItUm1Hbk5rNF9EeU5WMExtckRvc2xJb25TRmxZYkFvdnYxR3lQNzVZMW5ybzBndkdDV1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026", "summary": "", "url": "https://finance.yahoo.com/news/aligos-therapeutics-announces-ten-abstracts-060500908.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T06:05:00+00:00", "published_display": "13 May 2026 06:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aligos-therapeutics-reports-recent-business-200500860.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T20:05:00+00:00", "published_display": "07 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aligos-therapeutics-announce-1st-quarter-200500763.html", "source_name": "GlobeNewswire", "published_at": "2026-04-30T20:05:00+00:00", "published_display": "30 Apr 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aligos-therapeutics-announces-inducement-grants-120000433.html", "source_name": "GlobeNewswire", "published_at": "2026-04-24T12:00:00+00:00", "published_display": "24 Apr 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Aligos hires get stock options for 10,700 shares under Nasdaq rule", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNbzFiNjU3eTRJSENGR2VzYlZnZkhyZ2lIZzBJUlNib24yaURKZW5EbnNWc1VPeHJ3aUhEMFlNcGFmc210QXZDMktQSXFUZ2M1anVjSXRZZGF2aXllRFpVdjdWbXpNWXZ5QzM3cVVzbTRfRjFVbFNUMGVReUNjak04VGRrWVI4NGUxZzJkRWFjbGtRQk5oeTZLM0lRY2d5Q0V4YXpBcTdBOVZudkFOX1FaZ2NQVzFJUzNyUmNlQldnM0w?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aligos Therapeutics stock surges on China licensing deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPRUtxQ0hmZGhZQy1feFp3S0Z4YW9EeURqZlpBLTNfTDZRVDN1eC1Fb2d5REFPcWtacndiOXlwZDhSRlpUSWVCZkVScHJGU2RYVy1vTDkzZm14ckxqVGZqcm5oendTWGlOZEwwLXZZUmNoSHVYY2V6MlR6ZjRTVXRGZGFBTG5FbGRPREFMNkhiS0ZDeEYteElNMzRRSWZVV19BLW9hYzRsN2QtclpXN2E4bjltRzJCR01sblE?oc=5", "source_name": "Investing.com", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "More than 90 million live with HBV in Greater China; Aligos signs deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQRkRhVDNmbHlRT3pHTUdLTUxVcUEzTXlBUEZSdFhDWnc3eC0wOTc0VEdXa3RmaFh1YXo1NGFhZnNaTmxBTTRvS2h3S2VheUtjUEZIUlJxalBQVWs5cHNfTjNnOHdqZG5iWi1FNDJFOEJvM1QwN01kNHFzb2R2UkxySVQ5Z25LOW9aNzVDYVZhVXVvQ1VJdF8zTjNrZFkzaFFoLTVKY3h1alZEZDZ0WTA1RHFCVmtYc0pncURVak1R?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOcEJlTHhkRmFpd3N1S2NaX0RIc1dkb0poWDcwbHk0SnMySnM1a3dKTzluS3IwY0ktamZqWnNNZkozYm5PV1FDLUVnLTBqR0JUNEhOM0tXaGx6dndXQ1c3eXAzUzhyLXhaRU9aQVF0ZmdadlFrQkY3eHZrNjJqbFVCalRQYkJBa1hydVE?oc=5", "source_name": "Market source", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "H.C. Wainwright Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $50", "summary": "H.C. Wainwright has reiterated its Buy rating for Aligos Therapeutics (ALGS.US) and maintained a target price of $50. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance and potential.", "url": "https://www.moomoo.com/news/post/72927973/hc-wainwright-maintains-aligos-therapeutics-algsus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-15T01:41:20", "published_display": "15 Jul 2026 01:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Aligos stock rating on trial enrollment By Investing.com", "summary": "H.C. Wainwright has reiterated a Buy rating and a $50.00 price target for Aligos Therapeutics Inc. following the completion of enrollment in its Phase 2 B-SUPREME trial for chronic hepatitis B virus infection. The trial over-enrolled participants, leading to an anticipated earlie", "url": "https://m.au.investing.com/news/stock-market-news/hc-wainwright-reiterates-aligos-stock-rating-on-trial-enrollment-93CH-4532149?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-07-14T11:58:16", "published_display": "14 Jul 2026 11:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Aligos stock rating on trial enrollment", "summary": "H.C. Wainwright has reiterated a Buy rating and a $50.00 price target for Aligos Therapeutics Inc. (NASDAQ:ALGS) after the company completed enrollment for its Phase 2 B-SUPREME trial, which is evaluating pevifoscorvir sodium for chronic hepatitis B. Aligos over-enrolled one coho", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-aligos-stock-rating-on-trial-enrollment-93CH-4790650", "source_name": "Investing.com", "published_at": "2026-07-14T07:54:00", "published_display": "14 Jul 2026 07:54", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection", "summary": "Aligos Therapeutics has announced the completion of enrollment for its Phase 2 B-SUPREME study of pevifoscorvir sodium, a treatment for chronic hepatitis B virus (HBV) infection. The study successfully enrolled both HBeAg+ and HBeAg- participants, with topline safety and efficacy", "url": "https://investingnews.com/aligos-therapeutics-announces-the-completion-of-enrollment-in-the-phase-2-b-supreme-study-of-pevifoscorvir-sodium-under-development-for-the-treatment-of-chronic-hbv-infection/", "source_name": "Investing News Network", "published_at": "2026-07-14T01:40:01", "published_display": "14 Jul 2026 01:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics (ALGS) Completes Enrollment for Phase 2 Stud", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPUHQ5UExrbVNvX2szNWlzaVpHcUFxNWoxTHFLTkRiMmtIcWJvU2w2N2o5RTBOYk1nRENOdnZvVHdwZTlxMkxRNUhPdmN2VnNLa3o3eUpLaGZ6R29kOGt3VkVOOGRjazZtSU1Ia0tkLTY0bmV0ZXdoSGw2VDJ2WTlXc0ZNWGVTb0NuZ3U4QlVVZWJIWXRraHhMZzFkTVRvQXhrUFZNag?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T13:05:38+00:00", "published_display": "13 Jul 2026 13:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics Completes Enrollment in Phase 2 Study of Potential Chronic Hepatitis B Treatment", "summary": "Aligos Therapeutics has announced the completion of enrollment for its Phase 2 study of ALG-000184, an investigational capsid assembly modulator for chronic hepatitis B (CHB). The study aims to evaluate the safety and efficacy of the treatment in patients with CHB, bringing the c", "url": "https://www.moomoo.com/news/post/72861717/aligos-therapeutics-completes-enrollment-in-phase-2-study-of-potential?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T13:42:16", "published_display": "13 Jul 2026 13:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos completes enrollment in phase 2 hepatitis B study", "summary": "Aligos Therapeutics Inc. has completed enrollment for its Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic hepatitis B, enrolling 131 HBeAg+ and 114 HBeAg- participants. The company expects topline safety and efficacy data by late Q3 2027. Aligos has also secured a lic", "url": "https://www.investing.com/news/company-news/aligos-completes-enrollment-in-phase-2-hepatitis-b-study-93CH-4788395", "source_name": "Investing.com", "published_at": "2026-07-13T12:11:43", "published_display": "13 Jul 2026 12:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pevifoscorvir HBV trial fully enrolled; first key data expected in late 3Q 2027", "summary": "Aligos Therapeutics announced the completion of enrollment for its global Phase 2 B-SUPREME study of pevifoscorvir sodium, targeting chronic hepatitis B virus (HBV) infection. Both HBeAg+ and HBeAg- cohorts are now fully enrolled, with 131 and 114 participants respectively. Topli", "url": "https://www.stocktitan.net/news/ALGS/aligos-therapeutics-announces-the-completion-of-enrollment-in-the-2wuvwz2xpj5t.html", "source_name": "Stock Titan", "published_at": "2026-07-13T11:59:43", "published_display": "13 Jul 2026 11:59", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avoiding Lag: Real-Time Signals in (ALGS) Movement", "summary": "This article provides a real-time analysis of Aligos Therapeutics Inc. (NASDAQ: ALGS) stock movement, highlighting a strong near and mid-term sentiment despite a weak long-term outlook. It identifies a mid-channel oscillation pattern and an exceptional 94.0:1 risk-reward setup, o", "url": "https://news.stocktradersdaily.com/news_release/149/Avoiding_Lag:_Real-Time_Signals_in_ALGS_Movement_071326022802_1783924082.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T02:28:00", "published_display": "13 Jul 2026 02:28", "sentiment": "positive", "sentiment_pct": 63, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALGS Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "The article provides an overview of Aligos Therapeutics Inc (ALGS) financial performance, focusing on its revenue breakdown, profitability margins, and a comparison with competitors. ALGS maintains a strong gross margin of 100.00% but shows negative operating and net margins, ind", "url": "https://intellectia.ai/en/stock/ALGS/financials", "source_name": "Intellectia AI", "published_at": "2026-07-10T01:12:13", "published_display": "10 Jul 2026 01:12", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX)", "summary": "Two healthcare companies, Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX), have received bullish analyst ratings. H.C. Wainwright reiterated a Buy rating for Aligos Therapeutics with a $50 price target, while Truist Financial and Barclays maintained Buy ratings for V", "url": "https://www.theglobeandmail.com/investing/markets/stocks/VRTX/pressreleases/3182754/analysts-offer-insights-on-healthcare-companies-aligos-therapeutics-algs-and-vertex-pharmaceuticals-vrtx/", "source_name": "The Globe and Mail", "published_at": "2026-07-09T11:39:59", "published_display": "09 Jul 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Aligos Therapeutics stock rating at buy", "summary": "H.C. Wainwright has reiterated a Buy rating and $50.00 price target for Aligos Therapeutics (NASDAQ: ALGS), citing the company's differentiated hepatitis B drug candidate, pevifoscorvir sodium. The firm noted that the B-SUPREME trial is nearing full enrollment, and topline primar", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-aligos-therapeutics-stock-rating-at-buy-93CH-4781357", "source_name": "Investing.com", "published_at": "2026-07-09T11:12:13", "published_display": "09 Jul 2026 11:12", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Aligos Therapeutics stock rating at buy By Investing.com", "summary": "H.C. Wainwright has reiterated its Buy rating and a $50.00 price target for Aligos Therapeutics (NASDAQ:ALGS), citing the potential of its hepatitis B drug candidate, pevifoscorvir sodium, as a differentiated therapy. The company's recent strategic partnership with Xiamen Amoytop", "url": "https://ca.investing.com/news/stock-market-news/hc-wainwright-reiterates-aligos-therapeutics-stock-rating-at-buy-93CH-4724997", "source_name": "Investing.com Canada", "published_at": "2026-07-08T11:10:53", "published_display": "08 Jul 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics stock jumps on $25M China licensing deal", "summary": "Aligos Therapeutics Inc. shares surged 21% after announcing a $25 million upfront payment from an exclusive licensing agreement with Xiamen Amoytop Biotech Co., Ltd. for its chronic hepatitis B drug, pevifoscorvir sodium, in Greater China. The deal also includes up to $420 millio", "url": "https://www.investing.com/news/stock-market-news/aligos-therapeutics-stock-jumps-on-25m-china-licensing-deal-93CH-4777342", "source_name": "Investing.com", "published_at": "2026-07-07T11:39:33", "published_display": "07 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 92, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics Stock Is Trending Overnight: Here's What's Going On With ALGS Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxPbEpWcXdoRzI0UnR0U0dhbGJXQmJBdERpeWQwa0FMbzQ2UzNrVUFLMzdsQzFGWENwRFBSakFRRnU2dThVUlJLUmtETmpPUjg1WGRZZHNVXzF0TWlDMnF6dHUzaGVKdFJib2xFOEtRUVRCeW9zdTEyRU5pRDNSQ19nTEFPYWplQ0FpVmhYUG9VbkZCSnRkWUhwRVpCS1h0U09jODBnLThVWmR6WjJraXotak11RlpReFItRV9tRlN3Vmk0QmozWEVPdEZyT2VYdXBXdWc?oc=5", "source_name": "Sahm", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal", "summary": "Aligos Therapeutics (ALGS) shares surged 21% after-hours following a $25 million upfront payment from its Chinese licensing partner, Xiamen Amoytop Biotech. This payment provides non-dilutive funding, bolstering Aligos's financial position, which stood at $54.9 million in cash as", "url": "https://www.tradingview.com/news/stocktwits:fe893c603094b:0-algs-stock-rallies-16-after-hours-on-25m-cash-boost-from-china-hepatitis-b-drug-deal/", "source_name": "TradingView", "published_at": "2026-07-06T23:40:12", "published_display": "06 Jul 2026 23:40", "sentiment": "positive", "sentiment_pct": 92, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics' Shares Rally Following $25M Payment From Xiamen Amoytop Biotech", "summary": "Aligos Therapeutics (ALGS) shares rallied after receiving a $25 million milestone payment from its partner Xiamen Amoytop Biotech. This payment was triggered by the investigational new drug (IND) approval for a new compound targeting chronic hepatitis B (CHB). The collaboration, ", "url": "https://www.moomoo.com/news/post/72541625/aligos-therapeutics-shares-rally-following-25m-payment-from-xiamen-amoytop?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-06T22:40:12", "published_display": "06 Jul 2026 22:40", "sentiment": "positive", "sentiment_pct": 94, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics stock jumps on $25M China licensing deal By Investing.com", "summary": "Aligos Therapeutics (NASDAQ: ALGS) saw its stock jump 21% in after-hours trading following a licensing deal with Xiamen Amoytop Biotech Co., Ltd., which includes a $25 million upfront payment. The agreement grants Amoytop exclusive rights to develop and commercialize pevifoscorvi", "url": "https://za.investing.com/news/stock-market-news/aligos-therapeutics-stock-jumps-on-25m-china-licensing-deal-93CH-4356977", "source_name": "Investing.com South Africa", "published_at": "2026-07-06T22:10:12", "published_display": "06 Jul 2026 22:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Gets $25 Million Upfront Payment From Licensing Deal", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/aligos-gets-25-million-upfront-203416268.html", "source_name": "MT Newswires", "published_at": "2026-07-06T20:34:16+00:00", "published_display": "06 Jul 2026 20:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection", "summary": "Aligos Therapeutics (Nasdaq: ALGS) has received a $25 million upfront payment from Xiamen Amoytop Biotech Co., Ltd. for the exclusive license of pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection. This deal also includes potential milestone paymen", "url": "https://investingnews.com/aligos-therapeutics-receives-upfront-payment-of-25m-usd-from-the-exclusive-license-deal-of-pevifoscorvir-sodium-in-greater-china-for-chronic-hepatitis-b-virus-infection/", "source_name": "Investing News Network", "published_at": "2026-07-06T20:40:12", "published_display": "06 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos receives $25M upfront payment from China licensing deal", "summary": "Aligos Therapeutics Inc. has received a $25 million upfront payment from its licensing agreement with Xiamen Amoytop Biotech Co., Ltd. for pevifoscorvir sodium in Greater China. The deal includes potential milestone payments of up to $420 million and royalties, extending Aligos's", "url": "https://www.investing.com/news/company-news/aligos-receives-25m-upfront-payment-from-china-licensing-deal-93CH-4777348", "source_name": "Investing.com", "published_at": "2026-07-06T20:39:35", "published_display": "06 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "China grants breakthrough status to Aligos\u2019 HBV drug after $25M deal", "summary": "Aligos Therapeutics has received a $25 million upfront payment from Amoytop for the exclusive license of pevifoscorvir sodium in Greater China for chronic hepatitis B. The drug has also been granted Breakthrough Therapy Designation in China, making it eligible for priority review", "url": "https://www.stocktitan.net/news/ALGS/aligos-therapeutics-receives-upfront-payment-of-25m-usd-from-the-3dzov2xu3pw6.html", "source_name": "Stock Titan", "published_at": "2026-07-06T19:39:34", "published_display": "06 Jul 2026 19:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Aligos Therapeutics stock surging today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNMFNVMWc1dmtuVldXNmJGT3hVbHIxck9xUGhtQUdfaHZhM3VibUZfdDVNRGtuRDluR2l5Y3dkZkdQR2lINlNiQmdvLXBpQ2pGcUNMNXNwczFOdGZqUlZ2QVlhMUJvbWVWNFdqanFsdEFKcmFUTzVPWU10NzJPX3FUbVlpUFZwSWgyU19IakpNclp1UnF4VVR0S0JONFY4WjFZX1dsUlQxS1U0ZFZN?oc=5", "source_name": "Investing.com", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Discipline and Rules-Based Execution in ALGS Response", "summary": "This article provides an in-depth analysis of Aligos Therapeutics Inc. (NASDAQ: ALGS), highlighting mixed sentiment and choppy conditions across various time horizons. It details specific institutional trading strategies, including position, momentum, and risk hedging, with defin", "url": "https://news.stocktradersdaily.com/news_release/151/Discipline_and_Rules-Based_Execution_in_ALGS_Response_070226012002_1782969602.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-02T01:40:11", "published_display": "02 Jul 2026 01:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics (ALGS) director granted 5,860 stock options at $5.50", "summary": "Aligos Therapeutics director Heather Preston was granted 5,860 stock options with an exercise price of $5.50 per share, expiring on June 25, 2036. These options will vest fully on the earlier of the first anniversary of the June 25, 2026 grant date or just before the company\u2019s 20", "url": "https://www.stocktitan.net/sec-filings/ALGS/form-4-aligos-therapeutics-inc-insider-trading-activity-22d149254b22.html", "source_name": "Stock Titan", "published_at": "2026-06-30T08:10:05", "published_display": "30 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics (ALGS) director granted 5,860 stock options at $5.50 strike", "summary": "Aligos Therapeutics director Margarita Chavez was granted 5,860 stock options with an exercise price of $5.50 per share, expiring in 2036. These options will vest 100% on the earlier of the first anniversary of the June 25, 2026 grant date or Aligos Therapeutics' 2027 annual stoc", "url": "https://www.stocktitan.net/sec-filings/ALGS/form-4-aligos-therapeutics-inc-insider-trading-activity-9f068ee6426a.html", "source_name": "Stock Titan", "published_at": "2026-06-30T07:41:04", "published_display": "30 Jun 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics (ALGS) director receives stock options for 5,860 shares at $5.50", "summary": "Aligos Therapeutics director Peter Hirth was granted stock options for 5,860 shares at an exercise price of $5.50 per share. These options will vest on the earlier of the first anniversary of the grant date or immediately before the 2027 annual stockholder meeting, provided conti", "url": "https://www.stocktitan.net/sec-filings/ALGS/form-4-aligos-therapeutics-inc-insider-trading-activity-742043c26357.html", "source_name": "Stock Titan", "published_at": "2026-06-30T07:41:04", "published_display": "30 Jun 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics (ALGS) director granted 5,860 options at $5.50 strike", "summary": "Aligos Therapeutics director Bridget A. Martell was granted 5,860 stock options at an exercise price of $5.50 per share. These options vest 100% on the earlier of the first anniversary of the grant date or immediately before the company's 2027 annual stockholder meeting, continge", "url": "https://www.stocktitan.net/sec-filings/ALGS/form-4-aligos-therapeutics-inc-insider-trading-activity-6b4e9c7f3db1.html", "source_name": "Stock Titan", "published_at": "2026-06-30T07:41:03", "published_display": "30 Jun 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Aligos (ALGS) granted option on 5,860 common shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQQTMteEFEcGJvMENkQlgyTDZ2T3FqcGFwVkZZZHhwOWRTbEREMXdLSEloMWJ0V2dmYzRPVW01bk0xY1pvVGFKenZDbnZXdHM3YVRCaEtBX2l3NVRBMVloRmVaT05vdi01aHI4OWlQek1xQmtKZXpqOWNlWFFHLS1BUG1JUmVqcUZzNFF1MHlQa09LblB6VWhfZjY5WTE3akhFRkhXdUpZNHUxVC12MFg4djhBZlgtX0kw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics (ALGS) director gets 5,860-share stock option grant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQT3Y1VTRGWHFZSG40RzliamJZbmlXbnVHZ05IX09mczVSTkN6QnNpa3ZQYWUtNlFMMGpDTEJLY0pkV1hXbGtOZmZacVlOcGx4OURqYWNOc0lUbUpZSExwNk9oS0pUak5BckZxcFZiU2ktRWtIQWdQTkpacGdINW85TXJTYmZ6eDJpNlY1M2E4WDZYM3IweFp5NEVENzctYVY2ZnFIS1pxc2RrVlBRUVUxSFVrZnRaYmZK?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics (ALGS) shareholders approve ESPP changes and annual say-on-pay", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQVDdnOHBkQ19FeVQwM040LWFVU3hEbHlfSUFWaFZvX1Fjd3BJakpieHM0Vk9pQklqWTB2Z19SQUtXZDdWS1VvUVR0WlNfTS1iRTlJamt1R1JBQmNlUWF3bmt0VFpzcTA1SzhqNnBtRXV1czNoTm5FdG5qSWJFdnZsekVmZklNTzkxT3JtWHYwTzZxaXlaNHpOdmtTRjZ1c1FNa2dJS1ZpUkl3NW84QVRlZldn?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics (NASDAQ: ALGS) CEO discloses 5.6% stake in Schedule 13D filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQX0NoVlNodnotTmR3U29jUGJrWFNqcmN6eWpMTnJSNDlJR2pDUkFteFJVWEpnRDdjYm5lSktSekExaVNFeWFqZUdpdGlLbFQzY2hkS0MwdHk1b0NfeE85RVR0XzlXVUI3ZlJDNzBnN3Z1U0dUNkxJNzZsOE1BWVN3MGxUaks4MW9KSHp5QS04Z09JWURYU2R3VmdqOF9ZTXNzNEFVTXZsSWllMnlPeWtoMXpVSjlLMERDa05JQzFKYU5NcXpzZ3plNkZB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're A Bit Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxOamVpVUtMLXUxN3ZhSFhKYjBaTjFtZ0V2NkNVdjlCdzhTUUNuWW5seWIwbU5HcXAtaTFqUHVjUUpIM1kxcUt0WXBiSHdZV21HMm56N1EwQk9LbUlDS25hTERuYnB3eEEyZ3hOdGx3elNBUGR0MUwxT1RQVC02ZURvaXJyRDEyZXpTeC12QXI1eTU1WGpNX3NJZTRiY3BUbzM1aXFfSERHUmVTdFh2NDV6M01pLTNld2FvU0g0NmFIQkFjbHp5MzZyNUo1bG1mWVNxR20zMVk2d1ZkVUQyMGRISk9wWTVON0ZwZ1Y40gHwAUFVX3lxTE56aGprTDUwN0duS2F6ZWlERkZzTnVTWUdobXp6bzh5T096QVV5QjY5b1JfM2F5Ny1DTjNxOW16cDdMbkpTQnVVMFJCX3FsTHBJNzg3bjl2SExoTW9jWWY4cWt6MlRhcEkxSDljUDl4RGNEVHBTNldYTmo4bEt3S0doanhrR1ZVbkVEYS1qeDE1SWZxR0RXZTRCTlNVVkNwTHhSZklKcFNjUUNPN2dhY2YyZjN3c0VROW5CTHo2ZEtQS0RONEF6Vkxha1hEdzIyNzFpWjQtc1F2NFJRWS04T3NXejdJUHU4V0EtaXVMbkJiNw?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-06T07:00:00+00:00", "published_display": "06 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Lake Street Initiates Aligos Therapeutics With Buy Rating, $45 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/lake-street-initiates-aligos-therapeutics-120449124.html", "source_name": "MT Newswires", "published_at": "2026-05-28T12:04:49+00:00", "published_display": "28 May 2026 12:04", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hepatitis B data: 40% on Aligos drug reach HBsAg level used for cure regimens", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOeGlMbWo2OTZrd3VzSWhWRnJ1ZUJjaTh6WVpUcWllZktoQ213eUxwSU83Yjh4b09qdVhHWXRMY2tWVjhkM1AyNGV0bFZBaVlwX1FBbmRFcmRIU2xqdlh6TnNXZkpnNWR1U2VONzJVWS1iQktPdFdPOUxOeGVMWVFxZy1sVXBUZVItUm1Hbk5rNF9EeU5WMExtckRvc2xJb25TRmxZYkFvdnYxR3lQNzVZMW5ybzBndkdDV1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026", "summary": "", "url": "https://finance.yahoo.com/news/aligos-therapeutics-announces-ten-abstracts-060500908.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T06:05:00+00:00", "published_display": "13 May 2026 06:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aligos-therapeutics-reports-recent-business-200500860.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T20:05:00+00:00", "published_display": "07 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aligos-therapeutics-announce-1st-quarter-200500763.html", "source_name": "GlobeNewswire", "published_at": "2026-04-30T20:05:00+00:00", "published_display": "30 Apr 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aligos-therapeutics-announces-inducement-grants-120000433.html", "source_name": "GlobeNewswire", "published_at": "2026-04-24T12:00:00+00:00", "published_display": "24 Apr 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Aligos hires get stock options for 10,700 shares under Nasdaq rule", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNbzFiNjU3eTRJSENGR2VzYlZnZkhyZ2lIZzBJUlNib24yaURKZW5EbnNWc1VPeHJ3aUhEMFlNcGFmc210QXZDMktQSXFUZ2M1anVjSXRZZGF2aXllRFpVdjdWbXpNWXZ5QzM3cVVzbTRfRjFVbFNUMGVReUNjak04VGRrWVI4NGUxZzJkRWFjbGtRQk5oeTZLM0lRY2d5Q0V4YXpBcTdBOVZudkFOX1FaZ2NQVzFJUzNyUmNlQldnM0w?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-24T07:00:00+00:00", "published_display": "24 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aligos Therapeutics stock surges on China licensing deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPRUtxQ0hmZGhZQy1feFp3S0Z4YW9EeURqZlpBLTNfTDZRVDN1eC1Fb2d5REFPcWtacndiOXlwZDhSRlpUSWVCZkVScHJGU2RYVy1vTDkzZm14ckxqVGZqcm5oendTWGlOZEwwLXZZUmNoSHVYY2V6MlR6ZjRTVXRGZGFBTG5FbGRPREFMNkhiS0ZDeEYteElNMzRRSWZVV19BLW9hYzRsN2QtclpXN2E4bjltRzJCR01sblE?oc=5", "source_name": "Investing.com", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "More than 90 million live with HBV in Greater China; Aligos signs deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQRkRhVDNmbHlRT3pHTUdLTUxVcUEzTXlBUEZSdFhDWnc3eC0wOTc0VEdXa3RmaFh1YXo1NGFhZnNaTmxBTTRvS2h3S2VheUtjUEZIUlJxalBQVWs5cHNfTjNnOHdqZG5iWi1FNDJFOEJvM1QwN01kNHFzb2R2UkxySVQ5Z25LOW9aNzVDYVZhVXVvQ1VJdF8zTjNrZFkzaFFoLTVKY3h1alZEZDZ0WTA1RHFCVmtYc0pncURVak1R?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOcEJlTHhkRmFpd3N1S2NaX0RIc1dkb0poWDcwbHk0SnMySnM1a3dKTzluS3IwY0ktamZqWnNNZkozYm5PV1FDLUVnLTBqR0JUNEhOM0tXaGx6dndXQ1c3eXAzUzhyLXhaRU9aQVF0ZmdadlFrQkY3eHZrNjJqbFVCalRQYkJBa1hydVE?oc=5", "source_name": "Market source", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 86, "total_relevant": 52, "sentiment_summary": {"positive": 18, "negative": 3, "neutral": 31, "score": 59, "total": 52, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 72, "events": [{"event": "general", "label": "Market update", "weight": 9.35, "count": 17}, {"event": "deals", "label": "Deals and strategy", "weight": 5.5, "count": 10}, {"event": "earnings", "label": "Earnings", "weight": 5.36, "count": 12}, {"event": "analyst", "label": "Analyst action", "weight": 3.85, "count": 7}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}], "positive_events": 18, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 6.62, "latest_week": "2026-07-10", "one_week_move": 18.4, "four_week_move": 25.4, "twelve_week_move": -0.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.227031, "market_dynamics_buy_signal": false, "relative_strength": -30.203611, "fair_value_gap": -52.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 45.7255, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+18.4% over one week, +25.4% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 13}, {"label": "Market source", "count": 7}, {"label": "Investing.com", "count": 7}, {"label": "GlobeNewswire", "count": 4}, {"label": "Moomoo", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Investing News Network", "count": 2}, {"label": "Stock Traders Daily", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 17}, {"label": "Earnings", "count": 12}, {"label": "Deals and strategy", "count": 10}, {"label": "Analyst action", "count": 7}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 2}, {"label": "Balance sheet", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "72/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+18.4% over one week, +25.4% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "H.C. Wainwright Maintains Aligos Therapeutics(ALGS.US) With Buy Rating, Maintains Target Price $50"}], "updated_at": "2026-07-18T03:15:31.274285+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}